Dr. Ron Peck is Chief Medical Officer at Arvinas. Dr. Peck brings more than twenty years of clinical and drug development experience, most recently serving as Senior Vice President, Clinical Research at Tesaro, where he oversaw all clinical development efforts for the company’s entire pipeline, including Zejula® (niraparib) and Tesaro’s immuno-oncology programs.
Prior to his work at Tesaro, Dr. Peck served as the CMO of Kolltan Pharmaceuticals, a privately held clinical-stage biotech where he oversaw the clinical development of monoclonal antibodies targeting receptor tyrosine kinases. Dr. Peck began his industry career at Bristol Myers Squibb (BMS), where he spent 15 years in drug development, eventually serving as Vice President, YERVOY® (ipilimumab) Global Development Lead. At BMS, he played a key role in the approval and commercialization of YERVOY® (ipilimumab) across all indications and contributed to the successful development of multiple other oncology assets, including IXEMPRA® (ixabepilone). Early in his BMS career, Dr. Peck contributed to the life cycle development of ABILIFY® (aripiprazole) within the neuroscience clinical research organization.
Dr. Peck received his bachelor’s degree in chemistry from Georgetown University in Washington, D.C., his M.D. from Thomas Jefferson University Medical College in Philadelphia, PA., and completed a residency and hematology/oncology fellowship at Georgetown University in Washington, D.C before serving as Assistant Professor of Medicine at the University of Virginia.
What is Ronald Peck's net worth?
The estimated net worth of Ronald Peck is at least $1.25 million as of February 23rd, 2024. Dr. Peck owns 67,516 shares of Arvinas stock worth more than $1,247,696 as of December 21st. This net worth evaluation does not reflect any other assets that Dr. Peck may own. Learn More about Ronald Peck's net worth.
How do I contact Ronald Peck?
Has Ronald Peck been buying or selling shares of Arvinas?
Ronald Peck has not been actively trading shares of Arvinas during the last quarter. Most recently, Ronald Peck sold 1,699 shares of the business's stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $47.05, for a transaction totalling $79,937.95. Following the completion of the sale, the insider now directly owns 67,516 shares of the company's stock, valued at $3,176,627.80. Learn More on Ronald Peck's trading history.
Who are Arvinas' active insiders?
Are insiders buying or selling shares of Arvinas?
In the last year, insiders at the sold shares 3 times. They sold a total of 8,597 shares worth more than $404,488.85. The most recent insider tranaction occured on February, 23rd when CEO John G Houston sold 5,196 shares worth more than $244,471.80. Insiders at Arvinas own 5.2% of the company.
Learn More about insider trades at Arvinas. Information on this page was last updated on 2/23/2024.
